Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04969276 · ClinicalTrials.gov registry record · Phase 2
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 306
- Enrollment target
NCT04969276 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 306 participants.
The verdict
NCT04969276, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 306 participants
- Enrollment target
Study Summary
The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine administered concomitantly or singly in adults 65 years of age and older having received their second dose of the 2-dose schedule of Moderna COVID-19 vaccine at least 5 months before enrollment in the study.
Interventions
- BIOLOGICAL Quadrivalent Inactivated Influenza High Dose
- BIOLOGICAL COVID-19 mRNA Vaccine (nucleoside modified)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2022-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04969276
The ClinicalTrials.gov registry entry for NCT04969276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quadrivalent Inactivated Influenza High Dose is the first listed.
NCT04969276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04969276 about?
NCT04969276 is a clinical study titled "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine". The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine administered concomitantly or singly in adults 65 years of age and older ...
What is the current status of trial NCT04969276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 306 participants. The study started on 2021-07-16. Estimated completion is 2022-02-08.
What interventions are being tested in trial NCT04969276?
The interventions under investigation include: Quadrivalent Inactivated Influenza High Dose (BIOLOGICAL), COVID-19 mRNA Vaccine (nucleoside modified) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04969276?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.